Geron (GERN) AI Stock Analysis

• Market Cap: $937.89M
• Dividend Yield: N/A
• Average Volume (3M): 10.25M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: 11877.28%
• EPS Growth: 63.14%
• Country: US
• Employees: 229
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 638,017,100
• 10 Day Avg. Volume: 5,261,952
• 30 Day Avg. Volume: 10,254,656
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: 4.86
• Enterprise Value/Gross Profit: 4.96
• Enterprise Value/Ebitda: -12.53
• 1Y Price Target: $3.08
• Price Target Upside: 120.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 54 Neutral
• Price Target: $1.50 ▲(7.14% Upside)

Geron's overall stock score reflects strong revenue growth and strategic initiatives, particularly in the commercialization of RYTELO. However, significant profitability challenges and valuation concerns weigh on the score. The recent CEO appointment and positive earnings call sentiment provide some optimism for future performance.

Positive Factors

Leadership Changes

The hiring of new CEO Harout Semerjian, who has extensive commercial leadership experience, is seen as a positive change.

Revenue Performance

Rytelo sales of $49M came in above expectations with strong growth in patient demand.

Strategic Efforts

Geron's strategic efforts are showing positive impact with broadening uptake through 400 new accounts and re-ordering among two-thirds of accounts.

Negative Factors

Inventory Impact

Q1 Rytelo sales of $39MM were impacted by inventory drawdown, but demand remained flat.

Sales Performance

Geron reported Q1 Rytelo net sales of $39MM, which is below the estimate of $49MM and consensus of $48MM.

Geron Business Overview & Revenue Model

Company Description

Geron Corporation (GERN) is a biopharmaceutical company focused on the development of innovative therapies for cancer treatment. The company specializes in telomere biology and is primarily engaged in the research and development of drugs that target telomerase, an enzyme that plays a crucial role in cancer cell immortality. Geron's lead product candidate, imetelstat, is an investigational telomerase inhibitor being studied for its potential to treat hematologic malignancies, particularly myelofibrosis and acute myeloid leukemia.

How the Company Makes Money

Geron generates revenue primarily through collaborations, partnerships, and potential future product sales. The company has engaged in strategic collaborations with larger pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on product sales. As Geron advances its clinical trials and potentially gains regulatory approval for its drug candidates, it may also start to generate revenue from product sales. Additionally, the company may receive funding through grants and research contracts, especially if its therapies demonstrate significant promise in clinical trials.

Geron Financial Statement Overview

Summary

Geron's financials show significant challenges with profitability, marked by negative net income and EBIT margins. Despite revenue growth, the company faces persistent net losses and negative cash flows, indicating financial strain and sustainability concerns.

Income Statement

Geron's income statement reveals significant challenges with profitability, as highlighted by negative net income and EBIT margins over the periods analyzed. Despite a sharp increase in total revenue in the TTM period, the company still reports significant net losses, affecting its overall profitability. This indicates ongoing financial strain likely due to high operational costs or expenses exceeding revenue gains.

Balance Sheet

The balance sheet indicates moderate financial health with a relatively stable debt-to-equity ratio. The company's equity ratio shows a reasonable proportion of equity financing, though total liabilities have been increasing, reflecting potential leverage concerns. However, the consistent increase in total assets suggests investment and growth potential.

Cash Flow

Geron's cash flow statements highlight negative free cash flow and operating cash flows, indicating cash burn likely due to ongoing investments or operational challenges. Although there are positive financing cash flows, the inability to generate positive operating cash flow is concerning for long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	164.45M	76.99M	237.00K	596.00K	1.39M	253.00K
Gross Profit	161.21M	75.74M	-123.50M	-272.00K	610.00K	-49.80M
EBITDA	-63.78M	-154.85M	-174.78M	-134.15M	-111.59M	-73.92M
Net Income	-88.01M	-174.57M	-184.13M	-141.03M	-120.95M	-75.61M
Balance Sheet
Total Assets	555.20M	594.46M	394.08M	190.57M	226.03M	270.73M
Cash, Cash Equivalents and Short-Term Investments	387.98M	406.57M	333.70M	173.11M	183.72M	196.64M
Total Debt	121.84M	121.72M	85.90M	55.75M	55.00M	29.72M
Total Liabilities	295.67M	313.46M	146.13M	110.58M	99.62M	59.78M
Stockholders Equity	259.53M	280.32M	247.95M	80.00M	126.42M	210.95M
Cash Flow
Free Cash Flow	-178.28M	-219.30M	-168.57M	-127.81M	-95.76M	-67.05M
Operating Cash Flow	-178.28M	-218.62M	-167.74M	-127.38M	-95.56M	-66.65M
Investing Cash Flow	-31.31M	-106.00M	-180.32M	62.07M	71.95M	-105.32M
Financing Cash Flow	171.09M	334.37M	362.02M	87.26M	48.56M	168.35M

Geron Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GERN, the sentiment is Neutral. The current price of 1.4 is below the 20-day moving average (MA) of 1.41, above the 50-day MA of 1.35, and below the 200-day MA of 2.10, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 51.26 is Neutral, neither overbought nor oversold. The STOCH value of 37.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GERN.

Geron Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GERN	54 Neutral	$937.89M	―	-31.09%	―	11877.28%	63.14%
QURE	54 Neutral	$933.29M	―	-427.47%	―	-48.25%	33.77%
Sector *	51 Neutral	$7.90B	-0.33	-41.69%	2.23%	23.45%	-1.99%
SNDX	48 Neutral	$1.41B	―	-113.22%	―	2133.71%	-15.38%
CRMD	47 Neutral	$1.11B	19.61	38.35%	―	14970.29%	―
ANAB	44 Neutral	$577.02M	―	-343.83%	―	304.17%	29.37%
AVBP	39 Underperform	$804.89M	―	-50.13%	―	―	-79.41%

Geron Corporate Events

Geron Appoints Harout Semerjian as New CEO

On August 1, 2025, Geron Corporation’s Board of Directors appointed Harout Semerjian as the new President and CEO, effective August 7, 2025, replacing Dawn C. Bir. Mr. Semerjian brings extensive experience from his previous roles in the biotechnology and pharmaceutical sectors, including leadership positions at GlycoMimetics, Immunomedics, and Ipsen Pharma. The appointment is accompanied by an employment agreement that includes a substantial compensation package and stock options, reflecting the company’s strategic focus on strengthening its leadership team. Additionally, the company amended its severance plan and inducement award plan to align with these leadership changes, indicating a commitment to attracting and retaining top talent in the industry.

Geron Approves Key Proposals at Annual Meeting

On May 21, 2025, Geron Corporation held its annual stockholders meeting where several key proposals were approved. The meeting, conducted virtually, saw stockholders approve amendments to the company’s 2018 Equity Incentive Plan and 2014 Employee Stock Purchase Plan, increasing the number of shares issuable under these plans by 20,000,000 and 6,000,000 respectively. Additionally, the stockholders elected two Class II directors and ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.